Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals

Cancer Investigation

Volumn 30, Issue 2, 2012, Pages 189-197

  Hocker, James R ^a   Bishop, Erin A ^a   Lightfoot, Stan A ^a   Lerner, Megan R ^a   Peyton, Marvin D ^a   Brackett, Daniel J ^a   Hanas, Rushie J ^a   McMeekin, D Scott ^a   Walker, Joan L ^a   Hanas, Jay S ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Early detection; Electrospray ionization mass spectrometry; Leave one out cross validation; Ovarian cancer; Serum profiling

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SERUM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863397497     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.636115     Document Type: Article

References (29)

1. Nossov V, Amneus M, Su F, Lang J, Tran-Janco JM, Reddy ST, Farias-Eisner R.The early detection of ovarian cancer: fromtraditional methods to proteomics: Can we really do better than serum CA-125? Am J Obstet & Gynecol 2008;199:215-223.
2. American Cancer Society. Cancer facts & figures 2010. Atlanta, GA: American Cancer Society, Inc. 2010. Available from: http:// www.cancer.org/ docroot/STT/content/STT 1x Cancer Facts Figures 2010.asp?from=fast
3. Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, HolzgreveW, Zhong XY. Proteomics and biomarkers for ovarian cancer diagnosis. Annals Clin & Lab Sci 2010;40, 218-225.
4. NCCN & Clinical Resources Web site. NCCN clinical practice guidelines in oncology (NCCN Guidelines), genetic/familial high-risk assessment: breast and ovarian. Heredity breast and/or ovarian cancer, version 1, 2010. Available from: http://www. nccn.org/professionals/physician gls/f guidelines.asp. Accessed August 21. 2010.
5. Hausler SFM, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Honig A, Scheffler M, Dietl J, Wischhusen J. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Brit J Cancer 2010;103, 693-700.
6. Su F, Farias-Eisner R, Reddy S. Validation of candidate serum ovarian cancer biomarkers for early detection. Biomarkers Insights 2007;2, 369-375.
7. Richter R, Schuz-Knappe P, Schrader M, Standker L, Jurgens M, TammenH, ForssmannWG.Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatog B Biomed Sci Appl 1999;726, 25-35. (Pubitemid 29187202)
8. Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, Morgan DL, Denson KD, Prejeant KC, Gusev Y, Smith BJ, HanasRJ, PostierRG, Brackett DJ. Biomarker identification in human pancreatic cancer sera. Pancreas 2008;36:61-69.
9. Chambers G, Lawrie L, Cash P, Murray GL. Proteomics: A new approach to the study of disease. J Pathol 2000;192:280-288.
10. Verma M, Wright GL Jr, Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Annal NY Acad Sci 2001;945:103-115. (Pubitemid 33022438)
11. West-Norager M, Bro R,Marini F, Hogdall EV, Hogdall CK, Nedergaard L, Heegaard NH. Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. Anal Chemist 2009;81:1907-1913.
12. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument- Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P.Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-284. (Pubitemid 43121812)
13. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, GrizzleWE, Izbicka E, Kagan J, Malik G, McLerranD,Moul JW, PartinA, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Thompson I,WelshMJ,White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-112. (Pubitemid 40024018)
14. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformat 2003;4:24.
15. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51:3-5. (Pubitemid 40024002)
16. Yang SY, Xiao XY, ZhangWG, Zhang LJ, ZhangW, Zhou B, Chen G, He DC. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005;5:1-7.
17. Li J,Zhang Z, Rosenzweig J,WangYY,ChanDW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;481:296-304.
18. Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, Zhang WH, Peng CH, Zhang SD, Li HW, Chen GQ. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncol 2005;68:79-86. (Pubitemid 40675013)
19. Hocker JR, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Quillet A, Hanas RJ, Peyton MD, Postier RG, Brackett DJ, Hanas JS. Distinguishing early clinical stages of pancreatic cancer using Serum profiling. Cancer Invest 2011;29:173-179.
20. RansohoffDF. Rules of evidence for cancermolecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-314. (Pubitemid 38525286)
21. Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, McDonald JF, Ferńandez FM. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics 2009;10:259-274.
22. Sobin LH, Wittekind C. International Union against Cancer; TNM: Classification ofMalignant Tumors, 6th edition. New York, NY:Wiley-Liss, 2002.
23. Altman DG, Bland M. Statistics notes: diagnostic tests 2: predictive values. Brit Med J 1994;309:102. (Pubitemid 24216428)
24. Altman DG, Bland M. Statistics notes: diagnostic tests 1: sensitivity and specificity. Brit Med J 1994;308:1552. (Pubitemid 24178459)
25. National Committee for Clinical Laboratory Standards. User evaluation of precision performance of clinical chemistry devices. NCCLS Tentative Guideline EP5-T 2004.
26. Postier RG, Lerner MR, Lightfoot SA, Vannarath R, Lane MM, Hanas JS, Brackett DJ. DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem 2003;51:303-309. (Pubitemid 36245986)
27. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM,Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med 2008;5:1749-1760.
28. Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clinic Proceed. 2010;85:1111-1120.
29. Hocker JR, Peyton MD, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Bates-Albers LM, Vu NT,Hanas RJ, Kupiec TC, Brackett DJ, Hanas JS. Serum profiling of stage I/II lung cancer patients using electrospray ionizationmass spectrometry. Lung Cancer 2011;74:206-211.